DEL CASERÍO ME FÍO

Creo que ustedes son conscientes de la credibilidad de la información que pueda dar a la opinión pública una empresa contratada por el Partido Popular que se dedique a hacer una auditoría acerca de los sobresueldos a la cúpula del partido.

Creo que ustedes son conscientes de la credibilidad de la información que pueda dar a la opinión pública una empresa contratada por la Consejería de Sanidad de la Comunidad de Madrid acerca de la viabilidad del modelo de gestión sanitaria privado.

Creo que ustedes son conscientes de la credibilidad de la información que pueda dar al colectivo sanitario una guía canadiense sobre la osteoporosis en la que al final de la misma se pueda dar cuenta de los conflictos de interés de los redactantes de esta manera.

Competing interests: All authors received consulting fees and travel support from Osteoporosis Canada during the preparation of this article. In addition, Alexandra Papaioannou has been an advisory board member for Amgen, Eli Lilly, Merck Frosst, Novartis and Procter & Gamble; has served as a consultant to Amgen, Aventis Pharma, Eli Lilly, Lundbeck Canada Inc., Merck Frosst, Novartis, Procter & Gamble, Servier, Warner Chillcott and Wyeth Ayerst; has received unrestricted research grants from Amgen, Eli Lilly, Merck Frosst, Procter & Gamble and Sanofi-Aventis; has received clinicaltrial grants from Novartis and Pfizer; has received a research grant from the Ontario Ministry of Health and Long-Term Care; and has served as a member of the Continuing Medical Education Steering Committee of the Ontario College of Family Physicians. Suzanne Morin has been an advisory board member for Amgen, Eli Lilly, Novartis and Warner-Chilcott and has received speaker’s honoraria from Amgen, Novartis and Merck. Angela M. Cheung has been an advisory board member for Amgen and Eli Lilly; has served as a consultant for Merck; and has received speaker’s honoraria from Amgen, Eli Lilly, Merck, Novartis and Warner Chilcott. Stephanie Atkinson has served as a consultant to Pfizer and Wyeth Nutritionals and has participated in a multisite clinical trial funded by Novartis. Jacques P. Brown has been an advisory board member for Amgen, Eli Lilly, Merck, Novartis and Warner Chilcott; has served as a consultant for Amgen, Eli Lilly, Merck, Novartis and Warner Chilcott; has received grants from Abbott, Amgen, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Servier and Warner Chilcott; and has received speaker’s honoraria from Amgen, Eli Lilly, Merck, Novartis and Warner Chilcott. David A. Hanley has served as an advisory board member for Amgen Canada, Eli Lilly Canada, Novartis Canada, NPS Pharmaceuticals, Servier Canada and Warner Chilcott; has participated in clinical trials funded by Amgen, Eli Lilly, Novartis, NPS Pharmaceuticals, Pfizer, Servier and Wyeth Ayerst; and has received speaker’s honor aria from Amgen Canada, Eli Lilly Canada, Novartis Canada, NPS Pharmaceuticals and Servier Canada. Anthony Hodsman has been an advisory board member for Amgen Canada, Novartis Canada, Procter & Gamble Canada, Shire Pharmaceuticals Canada and Warner-Chilcott Canada; has served as a consultant to Cytochroma Canada; and has received speaker’s honoraria from McGill University and Novartis Canada. Stephanie M. Kaiser has served as an advisory board member for Amgen, AstaZeneca, Bristol Myers Squibb, Eli Lilly Canada, Merck Frosst/Schering, Novartis and Servier; has received speaker’s honoraria from Amgen, AstraZeneca, Eli Lilly, Merck Frosst/Schering Plough, Novartis, Procter and Gamble (now Warner Chilcott/Aventis), and Servier Canada; has received payment for development of educational presentations from Eli Lilly Canada Inc.; and has received travel funds for activities unrelated to this paper from Amgen Canada. Brent Kvern has been an advisory board member for the Alliance for Better Bone Health (sponsored by SanofiAventis and Warner) and for Amgen Canada; has served as a consultant for Servier Canada; has received honoraria from the Alliance for Better Bone Health, Amgen Canada, Eli Lilly, Merck Frosst Canada and Servier Canada; and has received payment for development of educational presentations from the Alliance for Better Bone Health, Amgen Canada, Eli Lilly, Merck Frosst Canada and Servier Canada. William D. Leslie has been an advisory board member for Amgen, Genzyme and Novartis; has received unrestricted research grants from Amgen, Genzyme, Merck Frosst, Procter & Gamble and Sanofi-Aventis; has received speaker’s fees from Amgen and Merck Frosst; and has received travel funds for activities unrelated to this paper from Genzyme. No additional competing interests declared for Sidney Feldman, Sophie Jamal and Kerry Siminoski.

La Medicina es una puta mentira. Otra más.